Cargando…
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Non-small-cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR) is a distinct subgroup of NSCLCs that is particularly responsive to EGFR tyrosine-kinase inhibitors (TKIs). A weighted pooled analysis of available studies was performed to evaluate clinical outcome in p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837609/ https://www.ncbi.nlm.nih.gov/pubmed/20015198 http://dx.doi.org/10.1111/j.1582-4934.2009.00991.x |
_version_ | 1782478316729532416 |
---|---|
author | Paz-Ares, Luis Soulières, Denis Melezínek, Ivan Moecks, Joachim Keil, Lorenz Mok, Tony Rosell, Rafael Klughammer, Barbara |
author_facet | Paz-Ares, Luis Soulières, Denis Melezínek, Ivan Moecks, Joachim Keil, Lorenz Mok, Tony Rosell, Rafael Klughammer, Barbara |
author_sort | Paz-Ares, Luis |
collection | PubMed |
description | Non-small-cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR) is a distinct subgroup of NSCLCs that is particularly responsive to EGFR tyrosine-kinase inhibitors (TKIs). A weighted pooled analysis of available studies was performed to evaluate clinical outcome in patients with EGFR-mutated NSCLC who were treated with chemotherapy or EGFR TKIs. Median progression-free survival (PFS) times were pooled from prospective or retrospective studies that evaluated chemotherapy or single-agent EGFR TKIs (erlotinib or gefitinib) in patients with NSCLC and EGFR mutations. Among the studies identified for inclusion in the analysis, 12 evaluated erlotinib (365 patients), 39 evaluated gefitinib (1069 patients) and 9 evaluated chemotherapy (375 patients). Across all studies, the most common EGFR mutations were deletions in exon 19 and the L858R substitution in exon 21. In the weighted pooled analysis, the overall median PFS was 13.2 months with erlotinib, 9.8 months with gefitinib and 5.9 months with chemotherapy. Using a two-sided permutation, erlotinib and gefitinib produced a longer median PFS versus chemotherapy, both individually (P= 0.000 and P= 0.002, respectively) and as a combined group (EGFR TKI versus chemotherapy, P= 0.000). EGFR TKIs appear to be the most effective treatment for patients with advanced EGFR-mutant NSCLC. Ongoing prospective trials comparing the efficacy of first-line chemotherapy and EGFR TKIs in EGFR-mutant disease should provide further insight into the most appropriate way to treat this specific group of patients. |
format | Online Article Text |
id | pubmed-3837609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-38376092015-04-24 Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis Paz-Ares, Luis Soulières, Denis Melezínek, Ivan Moecks, Joachim Keil, Lorenz Mok, Tony Rosell, Rafael Klughammer, Barbara J Cell Mol Med Reviews Non-small-cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR) is a distinct subgroup of NSCLCs that is particularly responsive to EGFR tyrosine-kinase inhibitors (TKIs). A weighted pooled analysis of available studies was performed to evaluate clinical outcome in patients with EGFR-mutated NSCLC who were treated with chemotherapy or EGFR TKIs. Median progression-free survival (PFS) times were pooled from prospective or retrospective studies that evaluated chemotherapy or single-agent EGFR TKIs (erlotinib or gefitinib) in patients with NSCLC and EGFR mutations. Among the studies identified for inclusion in the analysis, 12 evaluated erlotinib (365 patients), 39 evaluated gefitinib (1069 patients) and 9 evaluated chemotherapy (375 patients). Across all studies, the most common EGFR mutations were deletions in exon 19 and the L858R substitution in exon 21. In the weighted pooled analysis, the overall median PFS was 13.2 months with erlotinib, 9.8 months with gefitinib and 5.9 months with chemotherapy. Using a two-sided permutation, erlotinib and gefitinib produced a longer median PFS versus chemotherapy, both individually (P= 0.000 and P= 0.002, respectively) and as a combined group (EGFR TKI versus chemotherapy, P= 0.000). EGFR TKIs appear to be the most effective treatment for patients with advanced EGFR-mutant NSCLC. Ongoing prospective trials comparing the efficacy of first-line chemotherapy and EGFR TKIs in EGFR-mutant disease should provide further insight into the most appropriate way to treat this specific group of patients. Blackwell Publishing Ltd 2010 2009-12-08 /pmc/articles/PMC3837609/ /pubmed/20015198 http://dx.doi.org/10.1111/j.1582-4934.2009.00991.x Text en © 2009 F. Hoffman-La Roche Ltd. Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd |
spellingShingle | Reviews Paz-Ares, Luis Soulières, Denis Melezínek, Ivan Moecks, Joachim Keil, Lorenz Mok, Tony Rosell, Rafael Klughammer, Barbara Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis |
title | Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis |
title_full | Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis |
title_fullStr | Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis |
title_full_unstemmed | Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis |
title_short | Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis |
title_sort | clinical outcomes in non-small-cell lung cancer patients with egfr mutations: pooled analysis |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837609/ https://www.ncbi.nlm.nih.gov/pubmed/20015198 http://dx.doi.org/10.1111/j.1582-4934.2009.00991.x |
work_keys_str_mv | AT pazaresluis clinicaloutcomesinnonsmallcelllungcancerpatientswithegfrmutationspooledanalysis AT soulieresdenis clinicaloutcomesinnonsmallcelllungcancerpatientswithegfrmutationspooledanalysis AT melezinekivan clinicaloutcomesinnonsmallcelllungcancerpatientswithegfrmutationspooledanalysis AT moecksjoachim clinicaloutcomesinnonsmallcelllungcancerpatientswithegfrmutationspooledanalysis AT keillorenz clinicaloutcomesinnonsmallcelllungcancerpatientswithegfrmutationspooledanalysis AT moktony clinicaloutcomesinnonsmallcelllungcancerpatientswithegfrmutationspooledanalysis AT rosellrafael clinicaloutcomesinnonsmallcelllungcancerpatientswithegfrmutationspooledanalysis AT klughammerbarbara clinicaloutcomesinnonsmallcelllungcancerpatientswithegfrmutationspooledanalysis |